CRISPR-dCas9 Transactivator Vector for SCN1A Gene Expression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is no effective treatment to eliminate seizures in Dravet syndrome patients or to address the underlying cause of the disease, which is linked to heterozygous loss-of-function mutations in the SCN1A gene.

Innovation Solution

A vector is provided that comprises a transgene polynucleotide sequence encoding a sequence-specific DNA-targeting module fused to a transactivator, an enhancer polynucleotide sequence that restricts expression to SCN1A-expressing cells, and a promoter polynucleotide sequence, specifically targeting and increasing SCN1A expression in affected cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for Dravet syndrome, then patients receive standard epilepsy medications, but these treatments fail to eliminate seizures or address the underlying cause of the disease

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidability to address underlying cause

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses an intermediary system (CRISPR-dCas9-transactivator fusion protein) to deliver the transactivator function to the SCN1A gene regulatory region. This intermediary enables specific modulation of SCN1A expression without directly modifying the gene sequence, thereby addressing the underlying cause while maintaining treatment versatility

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the parameter of gene expression levels rather than attempting to correct the genetic mutation itself. By using epigenetic modulation to increase SCN1A transcript levels, the treatment addresses the haploinsufficiency mechanism while maintaining adaptability to different patient scenarios

Inventive Principle:

Principle #35Parameter changes

2Reliability

If gene editing approaches are used to correct SCN1A mutations, then the underlying cause could be addressed, but off-target effects and unintended genomic modifications may occur

Engineering Contradiction:

Improveprecision of gene targetingVSAvoidoff-target effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the nuclease domain from the Cas9 protein, retaining only the DNA-binding capability through the dCas9 variant. This removes the harmful cutting function while preserving the precise targeting ability, thereby eliminating off-target genomic modifications while maintaining reliable SCN1A-specific modulation

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention converts the potentially harmful nuclease activity into a beneficial epigenetic modulation tool. By using dCas9 fused to transactivators, the system leverages the precise targeting capability while transforming the outcome from DNA cleavage to controlled gene expression enhancement, eliminating harmful effects

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Quantity of substance

If SCN1A expression is increased in all brain cells, then overall SCN1A levels would improve, but non-specific expression may cause unwanted effects in cell types not affected by the disease

Engineering Contradiction:

ImproveSCN1A expression levelVSAvoidunwanted effects in unaffected cells

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by restricting the transgene expression specifically to SCN1A-expressing cells through cell-type-specific enhancer elements. This ensures that SCN1A modulation occurs only in the relevant cell populations (GABAergic interneurons) while preventing unwanted effects in other brain cell types

Inventive Principle:

Principle #3Local quality

4Productivity

If viral vectors are used to deliver the transgene, then efficient delivery to brain cells can be achieved, but immune responses and vector integration risks may occur

Engineering Contradiction:

Improvedelivery efficiencyVSAvoidimmune responses

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent employs disposable viral vectors that deliver the therapeutic payload and then are cleared from the system. The vectors serve their delivery function and are not permanently maintained, reducing the duration of immune exposure and integration risks while maintaining high delivery efficiency to target cells

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The vector effectively increases SCN1A expression in SCN1A-expressing cells, potentially normalizing brain function and reducing seizure symptoms associated with Dravet syndrome.

Implementation Method 1

the gRNA specifically hybridizes to a regulatory region of the SCN1A gene

Methodology Applied

Scientific EffectHybridization:

Implementation Method 2

the DTM comprises a nuclease-deficient CRISPR-associated protein

Methodology Applied

Scientific EffectCRISPR-Cas9 targeting:

Data Source

PatentUS20250082780A1Compositions for modulating expression of sodium voltage-gated channel alpha subunit 1 and uses thereof

Publication Date: 2025.03.13 REGEL THERAPEUTICS INC

AI summary

Provided herein are compositions and methods for increasing expression of the sodium voltage-gated channel alpha subunit 1 (SCN1A)gene in SCN1A-expressing cells. Further provided herein are uses of such compositions to treat disorders associated with SCN1A expression deficiency, such as Dravet syndrome.